| __timestamp | ACADIA Pharmaceuticals Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 59644696 |
| Thursday, January 1, 2015 | 90804000 | 79541000 |
| Friday, January 1, 2016 | 186456000 | 98015000 |
| Sunday, January 1, 2017 | 255062000 | 103958000 |
| Monday, January 1, 2018 | 265758000 | 103654000 |
| Tuesday, January 1, 2019 | 325638000 | 128951000 |
| Wednesday, January 1, 2020 | 388661000 | 135799000 |
| Friday, January 1, 2021 | 396028000 | 149883000 |
| Saturday, January 1, 2022 | 369090000 | 220206000 |
| Sunday, January 1, 2023 | 402466000 | 265542000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. Over the past decade, ACADIA Pharmaceuticals Inc. and Travere Therapeutics, Inc. have demonstrated contrasting strategies in optimizing these costs. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023, reflecting their aggressive expansion and investment in administrative capabilities. In contrast, Travere's expenses grew by approximately 345% during the same period, indicating a more conservative approach.
While ACADIA's strategy may suggest a robust growth trajectory, Travere's controlled spending could imply a focus on efficiency and cost management. This divergence highlights the strategic choices companies make in balancing growth with operational efficiency. As investors and stakeholders evaluate these companies, understanding their SG&A trends offers valuable insights into their long-term strategic priorities.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and ACADIA Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: MorphoSys AG vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.